Yi Xiao

机构：Shanghai Medical College of Fudan University, Fudan University Shanghai Cancer Center · ORCID：0000-0003-2946-9921

发表论文 56 篇 · 总被引 586 次 · h-index 12

代表论文

• Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial (2025 · Nature Medicine · 被引 39)
• HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer (2025 · Cell Metabolism · 被引 26)
• Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2− breast cancer (2025 · Cell Reports Medicine · 被引 26)
• Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 14)
• Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism (2025 · Nature Communications · 被引 12)
• Harnessing GPT-4 for automated error detection in pathology reports: Implications for oncology diagnostics (2025 · Digital Health · 被引 8)